Cargando…

Combination of vedolizumab and immunomodulators in ulcerative colitis

Detalles Bibliográficos
Autor principal:	Pinton, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290656/ https://www.ncbi.nlm.nih.gov/pubmed/34519096 http://dx.doi.org/10.1111/jgh.15686

Ejemplares similares

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021)

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
por: Schäffler, Holger, et al.
Publicado: (2017)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
por: Dart, Robin J, et al.
Publicado: (2017)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Immunomodulators and Immunosuppressants for Japanese Patients with Ulcerative Colitis
por: Bamba, Shigeki, et al.
Publicado: (2011)

Relapsing Polychondritis and Ulcerative Colitis
por: Almadi, Majid A., et al.
Publicado: (2010)

Unusual polyposis in ulcerative colitis
por: Amarapurkar, Anjali Deepak, et al.
Publicado: (2014)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
por: Wilson, Michele R, et al.
Publicado: (2017)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab
por: Yan, Jing, et al.
Publicado: (2023)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Role of EUS in idiopathic ulcerative colitis
por: Rana, Surinder Singh, et al.
Publicado: (2021)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review
por: Bhandari, Renu, et al.
Publicado: (2021)

Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
por: Hirsch, Ayal, et al.
Publicado: (2015)

A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
por: Kobayashi, Kiyonori, et al.
Publicado: (2018)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
por: Takatsu, Noritaka, et al.
Publicado: (2020)

Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis
por: Zhu, Wanwan, et al.
Publicado: (2022)

Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
por: Miyazaki, Haruka, et al.
Publicado: (2023)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cb011qkci94s1geo575b2d5i5m